Welcome to our dedicated page for Genpact SEC filings (Ticker: G), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Genpact's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Genpact's regulatory disclosures and financial reporting.
Genpact Ltd President and CEO Balkrishan Kalra reported multiple equity transactions. On March 4, 2026, he exercised an employee stock option for 2,800 common shares at $27.65 per share, then sold 2,800 common shares in an open‑market transaction at a weighted average price of $40.77, leaving 525,007 common shares held directly afterward.
On March 3, 2026, he also acquired 27,160 common shares as a grant or award at no cost, increasing his direct holdings. Footnotes note performance share units granted on March 15, 2023 that will vest on March 10, 2026, and 8,962 shares currently held under the employee stock purchase plan, including 587 shares bought since his prior Form 4.
Genpact LTD reported that Senior Vice President Sameer Dewan acquired 6,928 common shares through a grant/award transaction at a price of $0.00 per share. Following this award, he directly holds 61,207 common shares.
These shares relate to performance share units granted on March 15, 2023, for which the performance conditions have been satisfied. Each unit represents the right to receive one common share, and the units will vest on March 10, 2026, subject to his continued service.
Genpact LTD Senior Vice President and CHRO Piyush Mehta reported an equity award of 14,618 common shares. The shares relate to performance share units granted on March 15, 2023, for which performance conditions have been satisfied. These PSUs will vest on March 10, 2026, if he continues in service through that date.
Following this grant, Mehta directly holds 162,187 common shares, including 10,512 shares under Genpact’s Employee Stock Purchase Plan, of which 153 were acquired since his prior Form 4 filed on February 3, 2026.
Nanduru Anil reported acquisition or exercise transactions in this Form 4 filing.
Genpact LTD Senior Vice President Nanduru Anil reported an equity award of 13,856 common shares. These shares relate to performance share units granted on March 15, 2023, for which the performance conditions have been satisfied.
Each PSU represents the right to receive one common share. The units are scheduled to vest on March 10, 2026, subject to the executive’s continued service through that date. Following this award, Anil’s directly held stake is reported as 113,202 common shares.
Genpact LTD reported that Senior Vice President Riju Vashisht acquired 13,856 common shares at no cost through the settlement of performance share units granted on March 15, 2023. The transaction increased her directly held stake to 130,748 common shares.
The underlying performance share units will vest on March 10, 2026, subject to her continued service, with each unit representing the right to receive one common share.
Genpact LTD’s Chief Financial Officer, Michael Hal Weiner, reported acquiring 17,320 common shares on March 3, 2026 through a grant/award transaction at a price of $0.00 per share. These shares relate to performance share units granted on March 15, 2023, for which performance conditions have been satisfied. The performance share units will vest on March 10, 2026, subject to his continued service. Following this award, he beneficially owns 188,893 common shares, including 1,538 shares held under the Genpact Employee Stock Purchase Plan, of which 102 were acquired since his Form 4 filed on February 3, 2026.
Genpact Limited, a Bermuda-based advanced technology and business process company, reports 2025 total net revenues of $5.1 billion. Advanced Technology Solutions generated $1.2 billion, or 23.7% of net revenues, while Core Business Services contributed $3.9 billion, or 76.3%.
The company is pivoting heavily into AI and agentic solutions, embedding data and AI, digital technology and advisory services across its offerings. By industry, 2025 revenues were $1.4 billion from Financial Services (26.7%), $1.7 billion from Consumer and Healthcare (34.0%), and $2.0 billion from High Tech and Manufacturing (39.3%).
Genpact employs over 146,500 people in more than 35 countries and is scaling AI talent, with over 7,000 AI builders and nearly 20,000 AI practitioners. The company highlights significant risks around rapid AI adoption, cybersecurity, regulatory change, talent retention—its 2025 attrition rate was 24%—and geopolitical and economic uncertainty.
Genpact Limited furnished a Form 8-K to provide a press release announcing its financial results for the three months and full year ended December 31, 2025. The press release is included as Exhibit 99.1 and is incorporated by reference.
The company notes that the press release and related conference call include non-GAAP financial measures, and that reconciliations to the most directly comparable GAAP figures are provided in the press release. The information under Item 2.02 is furnished, not filed, so it is not subject to certain Exchange Act liabilities or automatically incorporated into other SEC filings.
Genpact Limited’s Chief Accounting Officer, Anthony J. Radesca, received an equity grant of 6,802 common shares on January 30, 2026, at a price of $0 per share. The award is in the form of restricted share units under the Genpact Limited 2017 Omnibus Incentive Compensation Plan.
Each RSU converts into one Genpact common share upon vesting. One-third of the shares will vest on each of January 10, 2027, January 10, 2028, and January 10, 2029, contingent on his continued service. Following this grant, he beneficially owns 26,868 common shares directly.